Beer company Boston Beer (NYSE:SAM) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 4.1% year on year to $385.7 million. Its GAAP loss of $2.12 per share was 15.3% above analysts’ consensus estimates.
Marketing technology company Zeta Global (NYSE:ZETA) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 25.4% year on year to $394.6 million. Guidance for next quarter’s revenue was optimistic at $370 million at the midpoint, 2.1% above analysts’ estimates.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.7% below analysts’ estimates. Its GAAP loss of $0.07 per share was 66.7% above analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.1% year on year to $1.20 billion. On the other hand, the company’s full-year revenue guidance of $4.38 billion at the midpoint came in 2.8% below analysts’ estimates. Its non-GAAP profit of $6.64 per share was 2.1% above analysts’ consensus estimates.
Snap stock has seen much better days, but the fundamentals tell a more complicated story. Discover whether this is a value trap or a rare turnaround opportunity.
Fragrance and perfume company Inter Parfums (NASDAQ:IPAR) announced better-than-expected revenue in Q4 CY2025, with sales up 6.8% year on year to $386.2 million. On the other hand, the company’s full-year revenue guidance of $1.48 billion at the midpoint came in 2% below analysts’ estimates. Its GAAP profit of $0.88 per share was 11.4% above analysts’ consensus estimates.
Data analytics and digital solutions company ExlService Holdings (NASDAQ:EXLS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 12.7% year on year to $542.6 million. On the other hand, the company’s full-year revenue guidance of $2.3 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was 7.5% above analysts’ consensus estimates.
Cybersecurity stocks plunged after Anthropic unveiled its AI code‑scanning tool, sparking fears of margin pressure, though analysts say the selloff overlooks the strengths of full‑scale runtime security platforms.
Latin American e-commerce and fintech company MercadoLibre (NASDAQ:MELI) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 44.6% year on year to $8.76 billion. Its GAAP profit of $11.03 per share was 3.6% below analysts’ consensus estimates.
Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.
In a report from Business Insider, Freedom Capital Markets chief market strategist Jay Woods said that updates on tariff policy, and plans of military action against Iran could impact markets.
